Your Search Results

Modern risk prediction in TAVI

21 May 2026 – From EuroPCR 2026

This session examines modern risk prediction models in transcatheter aortic valve implantation (TAVI). It presents novel scoring systems, the prognostic significance of cardiac damage extent and progression, and the impact of multivalvular disease, enhancing patient stratification and outcome prediction.

Overcoming complications with intracoronary imaging

21 May 2026 – From EuroPCR 2026

Explore challenging cases of intracoronary imaging complications, highlighting recognition, management, and resolution of complex vascular and mechanical issues encountered during coronary interventions.

How to achieve coronary patency during TAVI

21 May 2026 – From EuroPCR 2026

This session addresses techniques to achieve coronary artery patency during transcatheter aortic valve implantation (TAVI), highlighting advanced procedural approaches and management of high-risk anatomical scenarios.

Sealing the deal: catheter based solutions for aortic disease

21 May 2026 – From EuroPCR 2026

Examine catheter-based solutions for aortic disease management, featuring innovative approaches to preserving branch vessels, managing vascular complications, and repairing challenging aneurysms with endografts and occluders.

Cardiac dimensions receives Medical Device Regulation (MDR) certification for Carillon Mitral Contour System

25 Apr 2023

Mid-term echocardiographic outcomes following transapical mitral valve replacement: Updates from the Intrepid Pilot Study

19 Sep 2022

Pamela Gatto provides her take on the Intrepid Global Pilot Study which was presented by Renuka Jain at TCT Congress 2022.

Author

Pamela Gatto

Updates from the Intrepid Pilot Study: Mid-term Echocardiographic Outcomes Following Transapical Mitral Valve Replacement

RESHAPE-HF2 - Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure

01 Sep 2024

Nicola Ryan provides her take on the RESHAPE-HF2 trial presented by Stefan Anker at the ESC Congress 2024 in London and simultaneously published in the NEJM.

The RESHAPE-HF 2 trial is a prospective randomised control trial comparing transcatheter mitral valve repair (TEER) and guideline-directed medical therapy to guideline-directed medical...

Author

Nicola Ryan

Percutaneous coronary intervention of native coronary artery versus saphenous vein graft in patients with prior coronary artery bypass graft surgery (PROCTOR)

03 Nov 2025

Kalaivani Mahadevan and Trisha Singh provide their take on the PROCTOR study presented by Ruben de Winter at TCT 2025, in San Francisco.